T cell costimulation, checkpoint inhibitors and anti-tumor therapy

Abstract

The hallmarks of the adaptive immune response are specificity and memory. The cellular response is mediated by T cells which express cell surface T cell receptors (TCRs) that recognize peptide antigens in complex with major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs). However, binding of cognate TCRs with MHC-peptide complexes alone (signal 1) does not trigger optimal T cell activation. In addition to signal 1, the binding of positive and negative costimulatory receptors to their ligands modulates T cell activation. This complex signaling network prevents aberrant activation of T cells. CD28 is the main positive costimulatory receptor on naïve T cells; upon activation, CTLA4 is induced but reduces T cell activation. Further studies led to the identification of additional negative costimulatory receptors known as checkpoints, e.g. PD1. This review chronicles the basic studies in T cell costimulation that led to the discovery of checkpoint inhibitors, i.e. antibodies to negative costimulatory receptors (e.g. CTLA4 and PD1) which reduce tumor growth. This discovery has been recognized with the award of the 2018 Nobel prize in Physiology/Medicine. This review highlights the structural and functional roles of costimulatory receptors, the mechanisms by which checkpoint inhibitors work, the challenges encountered and future prospects.

Fast and frugal innovations in response to the COVID-19 pandemic

“…There have been some extraordinary moves. India and Pakistan are refitting their rolling stock of trains to become hospital wards for patients with COVID-19 1 . China constructed a 1,000-bed hospital in 10 days (ref.…”

Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System

“…In addition, further applications of whole tumor cell therapy are greatly hampered by the limitation of patient materials [57] and difficulties in vaccine preparation [55]. Over the last several years, the clinical potential of immune-based therapies in cancer treatment, including T cell checkpoint inhibitors, chimeric antigen receptor-based therapies, and dendritic cell-based cancer vaccines, has attracted much attention from investigators and investors [58,59]. The success of these immunotherapies is likely to have been the stimulus for the recent development of new cancer vaccines utilizing the concept of combination treatments [54,56,57,60,61].…”

OX40L–OX40 Signaling in Atopic Dermatitis

“…Full T cell activation requires three key signals: engagement of T cell receptors by antigen peptide-bound major histocompatibility complex, ligation of co-stimulatory molecules, and support from cytokines [1]. In addition, recent studies have stressed a cardinal role of co-inhibitory molecules in regulating excessive T cell activation [2][3][4][5]. There are several co-stimulatory and co-inhibitory molecules, also known as immune checkpoint molecules (Figure 1).…”